FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.
What happened
FDA reviewed records the firm submitted after three FDA records requests dated June 14, 2022, July 12, 2022, and July 28, 2023. FDA found the firm did not show identity testing of incoming components, did not test ethanol for methanol, did not include identity results in finished-product test reports, skipped microbiological testing because of high alcohol content, and lacked adequate stability data for a two-year shelf life.
What FDA found
The firm did not test each incoming component for identity and did not validate supplier test results; it also did not test ethanol lots for methanol.
21 CFR 211.84(d)(1) and 211.84(d)(2)Finished OTC drug batches were released without complete identity and strength testing, and the firm skipped microbiological testing based on high alcohol content.
21 CFR 211.165(a) and 211.165(b)The firm lacked adequate stability data to support its two-year expiry and did not evaluate stability batches for identity.
21 CFR 211.166(a)
What FDA wants
Respond in writing within 15 working days with corrective actions and records for component identity testing, finished-product release testing, and stability; if the firm intends to resume U.S. drug manufacturing, FDA recommends a qualified current good manufacturing practice (CGMP) consultant.
Who should pay attention
- brands and distributors buying OTC hand sanitizers from this contract manufacturer
- companies relying on supplier test reports for ethanol or other raw materials
- quality teams handling U.S. import alerts and supplier qualification
This is a summary. Read the original letter on fda.gov.